Patient specific quality assurance of RapidArc pre treatment plans using semiflex 0.125Â cc ionization chamber

Patient specific pre-treatment quality assurance for RapidArc plans were analyzed for hundred patients for different sites. Verification plan was created for each treatment plan in Eclipse 8.6 treatment planning system with the semiflex ionization chamber and the octavius phantom. Absolute point dose were measured for head and neck, thorax and abdomen cases using semiflex (0.125 cc) ionization chamber. Positive absolute mean dose variation of 0.56% was observed with thorax cases with a standard deviation (SD) of ±1.13 between the plans with a range of −1.78% to 2.70%. Negative percentage dose errors were found with head and neck and abdomen cases, with a mean variation of −0.43% (SD±1.50), (range −3.25% to 2.85%) and −0.35% (SD±1.48), (range −3.10% to 2.65%) for head and neck and abdomen cases respectively. Evaluation has been done using PTW verisoft software by keeping the passing criteria as 3 mm DTA, 3% DD, for 95% of the evaluated dose points. The maximum percentage value failed in gamma analysis was found to be 4.95, 4.75, and 4.88 for head and neck, thorax, and abdomen cases respectively. In all the cases analyzed the percentage dose points failed the gamma criteria is less than 5%. On the basis of the studies performed it can be concluded that the semiflex ionization chamber having a volume of 0.125 cc can be used efficiently for measuring the pre-treatment quality assurance of RapidArc plans for all the sites.